Research programme: cancer therapeutics - Critical Outcome Technologies/Merck Serono

Drug Profile

Research programme: cancer therapeutics - Critical Outcome Technologies/Merck Serono

Latest Information Update: 19 Aug 2009

Price : $50

At a glance

  • Originator Critical Outcome Technologies; Merck Serono
  • Developer Critical Outcome Technologies
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 17 Aug 2009 Discontinued for Cancer in Canada (unspecified route)
  • 09 Apr 2009 Research is ongoing in Cancer in Canada
  • 18 Oct 2007 Early research in Cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top